Unveiling the Expression of UNC13C in Brain and Glioblastoma Cells

Objective: Glioblastoma (GBM) is the most aggressive type of brain tumor, accounting approximately half of malignant central nervous system tumors. Median overall survival remains below 15 months post-diagnosis. Current treatments include surgical resection, radiotherapy, and chemotherapy, primarily with temozolomide, yet the median overall survival remains below 15 months post-diagnosis. Understanding the molecular mechanisms of GBM is essential for developing novel therapeutic approaches. Among the implicated genes, the UNC13 protein family, particularly UNC13C, is of interest. While UNC13A and UNC13B have been linked to various neurological disorders, UNC13C has been less studied despite its involvement in neurotransmitter release and potential tumor-suppressive effects in other cancers. Our previous work indicated low expression levels of UNC13C in glioblastoma cell lines compared to healthy brain tissue, suggesting a role in GBM pathogenesis. In this study, we aimed to comprehensively evaluate UNC13C expression using web based bioinformatics tools and experimental approaches. Methods: We analyzed UNC13C expression across various tissues via Correlation Analyzer, confirming in glioblastoma tissues compared to healthy brain samples using the GEPIA and UALCAN databases. Additionally, we assessed UNC13C levels in glioblastoma cell lines (LN-18, A-172, U-87), human microglia (HMC3), and healthy astrocytes through quantitative real-time polymerase chain reaction (qRT-PCR). Results: Our findings reveal that UNC13C expression is notably reduced in glioblastoma cells, with the highest expression observed in healthy astrocytes, albeit at low levels. These results underscore the importance of UNC13C in GBM and highlight the need for further investigation into its role in tumor development and progression. Conclusion: This study provides the first report of UNC13C expression detailed in human cell lines both normal and glioblastoma, emphasizing its significance from a developmental perspective.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Health Sciences
Published
2025-03-23
DOI
https://doi.org/10.33808/clinexphealthsci.1573250
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Unveiling the Expression of UNC13C in Brain and Glioblastoma Cells

Ömer Faruk Bayrak, Altay Burak Dalan, Didem Seven
Clinical and Experimental Health Sciences
Ferroptosis and cancer prognosis
article

Unveiling the Expression of UNC13C in Brain and Glioblastoma Cells

Ömer Faruk Bayrak, Altay Burak Dalan, Didem Seven
article en

Abstract

Objective: Glioblastoma (GBM) is the most aggressive type of brain tumor, accounting approximately half of malignant central nervous system tumors. Median overall survival remains below 15 months post-diagnosis. Current treatments include surgical resection, radiotherapy, and chemotherapy, primarily with temozolomide, yet the median overall survival remains below 15 months post-diagnosis. Understanding the molecular mechanisms of GBM is essential for developing novel therapeutic approaches. Among the implicated genes, the UNC13 protein family, particularly UNC13C, is of interest. While UNC13A and UNC13B have been linked to various neurological disorders, UNC13C has been less studied despite its involvement in neurotransmitter release and potential tumor-suppressive effects in other cancers. Our previous work indicated low expression levels of UNC13C in glioblastoma cell lines compared to healthy brain tissue, suggesting a role in GBM pathogenesis. In this study, we aimed to comprehensively evaluate UNC13C expression using web based bioinformatics tools and experimental approaches. Methods: We analyzed UNC13C expression across various tissues via Correlation Analyzer, confirming in glioblastoma tissues compared to healthy brain samples using the GEPIA and UALCAN databases. Additionally, we assessed UNC13C levels in glioblastoma cell lines (LN-18, A-172, U-87), human microglia (HMC3), and healthy astrocytes through quantitative real-time polymerase chain reaction (qRT-PCR). Results: Our findings reveal that UNC13C expression is notably reduced in glioblastoma cells, with the highest expression observed in healthy astrocytes, albeit at low levels. These results underscore the importance of UNC13C in GBM and highlight the need for further investigation into its role in tumor development and progression. Conclusion: This study provides the first report of UNC13C expression detailed in human cell lines both normal and glioblastoma, emphasizing its significance from a developmental perspective.

Clinical and Experimental Health SciencesVol. 15(1)
Yeditepe University (TR)
Openalex Percentile: Top 92%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.